The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer; GlaxoSmithKline; Pharmamar-zeltia
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Blueprint Medicines; Boehringer Ingelheim; GlaxoSmithKline; SpringWorks Therapeutics
Tumor volume and T2 hyperintensity changes from DeFi: A phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.
 
Thierry Alcindor
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; BMS; Merck
Research Funding - Astellas Pharma (Inst); Deciphera (Inst); EMD Serono (Inst); Epizyme (Inst); Karyopharm Therapeutics (Inst); SpringWorks Therapeutics (Inst)
 
Bernd Kasper
No Relationships to Disclose
 
Mrinal M. Gounder
Honoraria - Flatiron Health; Guidepoint Global; Med Learning Group; Medscape; More Health; PER; PER; touchIME
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Daiichi Sankyo; Epizyme; Karyopharm Therapeutics; Rain Therapeutics; Regeneron; Springworks Therapeutics; TYME
Speakers' Bureau - Amgen; Boehringer Ingelheim; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - GODDESS PRO Desmoid Tumor (Inst); UpToDate
Travel, Accommodations, Expenses - Epizyme
Other Relationship - Desmoid Tumor Research Foundation
(OPTIONAL) Uncompensated Relationships - Athenex; Foundation Medicine
 
Ravin Ratan
Stock and Other Ownership Interests - Johnson & Johnson/Janssen (I); Medtronic (I)
Honoraria - Peerview; touchIME
Consulting or Advisory Role - Epizyme
Research Funding - Ayala Pharmaceuticals (Inst); Bayer; Epizyme; SpringWorks Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - SpringWorks Therapeutics; SpringWorks Therapeutics
 
Winette T.A. Van Der Graaf
Consulting or Advisory Role - Agenus (Inst); Bayer (I); Novartis (I); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Research Funding - Lilly (Inst)
 
Breelyn A. Wilky
Consulting or Advisory Role - Adaptimmune; Adcendo; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Epizyme; Polaris; SpringWorks Therapeutics
Research Funding - Agenus; Exelixis
Travel, Accommodations, Expenses - Adaptimmune; Daiichi Sankyo; Deciphera
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; NanoCarrier; SpringWorks Therapeutics
 
Noah Federman
Stock and Other Ownership Interests - Moderna Therapeutics; Reata Pharmaceuticals
Consulting or Advisory Role - Bayer; Tempus
Speakers' Bureau - Bayer
Research Funding - Mirati Therapeutics
 
Agnese Peruzzi
Employment - Medpace
 
Stephanie Moody
No Relationships to Disclose
 
Allison Lim
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Brad Tumminello
Employment - SpringWorks Therapeutics
Stock and Other Ownership Interests - SpringWorks Therapeutics
Travel, Accommodations, Expenses - SpringWorks Therapeutics
 
Shivaani Kummar
Stock and Other Ownership Interests - Arxeon Therapeutics (I); PathomIQ
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Cadila Pharmaceuticals (I); EcoR1 Capital; Genome Insight; Gilead Sciences; Harbour BioMed; Mirati Therapeutics; Mundipharma; Oxford BioTherapeutics; Seagan; SpringWorks Therapeutics
Research Funding - ADC Therapeutics (Inst); ADC Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Day One Therapeutics (Inst); Dynavax Technologies (Inst); Elevation Oncology (Inst); Genome & Company (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Moderna Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Bayer
 
Patrick Schöffski
Consulting or Advisory Role - Adcendo; Amryt Pharma; Avacta Life Sciences; Biolumina; Boehringer Ingelheim; Boxer Capital; Cogent Biosciences; Curio Science; Deciphera; Eisai; Ellipses Pharma; Exelixis; Genmab; LLX Solutions; Medpace; Merck; Moleculin Biotech; PharmaMar; Regeneron; Sanofi; SERVIER; SQZ Biotechnology; Studiecentrum voor Kernenergie (SCK CEN); Transgene; UCB
Research Funding - Adcendo (Inst); CoBioRes NV (Inst); Eisai (Inst); G1 Therapeutics (Inst); Genmab (Inst); Merck (Inst); ONA therapeutics (Inst); PharmaMar (Inst); Sartar Therapeutics (Inst)